Arianna Barbetta, Brittany Rocque, Sarah Bangerth, Kelly Street, Carly Weaver, Shefali Chopra, Janet Kim, Linda Sher, Brice Gaudilliere, Omid Akbari, Rohit Kohli, Juliet Emamaullee
Allograft rejection is common following clinical organ transplantation, but defining specific immune subsets mediating alloimmunity has been elusive. Calcineurin inhibitor dose escalation, corticosteroids, and/or lymphocyte depleting antibodies have remained the primary options for treatment of clinical rejection episodes. Here, we developed a highly multiplexed imaging mass cytometry panel to study the immune response in archival biopsies from 79 liver transplant (LT) recipients with either no rejection (NR), acute T cell-mediated rejection (TCMR), or chronic rejection (CR)...
April 12, 2024: Science Advances